Menlo Park, CA, August 16, 2017 – Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced the completion of two Phase I studies using its proprietary AcuStream technology platform.
The first study was a single-day, single-dose study of topical delivery of a tropicamide-phenylephrine combination for pupil dilation. 20 subjects (40 eyes) were randomized to receive either a 30-microliter dose using standard eye drops or a 9-microliter dose using the AcuStream technology. The second study was a single-day, single-dose study of topical delivery of latanoprost for intraocular pressure reduction. 18 subjects (36 eyes) were randomized to receive either a 30-microliter dose using standard eye drops or a 9-microliter dose using the AcuStream technology.
“We are extremely pleased to have completed both of these studies with Kedalion’s AcuStream platform,” said Mark Blumenkranz, M.D., M.M.S., Executive Chairman of Kedalion. “As these are the first human clinical studies that have been conducted with AcuStream, the completion of these studies represents a significant milestone for the development of the platform and for the advancement of the company. We look forward to presenting these data at an upcoming conference.”
About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com.